October 2017

Clinerion, Provisio partner

Tuesday, October 31, 2017

Clinerion has expanded its geographic coverage to include over 60 million patients in the U.S., via a strategic partnership with Provisio. Clinerion now has a truly global footprint for its services for clinical trial patient search and identification, and data generation for real-world evidence and market access activities.

[Read More]

Michael J. Fox Foundation, 23andMe collaborate

Tuesday, October 31, 2017

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to participate in research. This cohort will provide researchers, drug makers, regulators and payers critical insight into the lived experience, genetics and variability of Parkinson’s disease. The study, Fox Insight (foxinsight.org), is open to anyone 18 or older worldwide with or without Parkinson’s disease and aims to recruit tens or even hundreds of thousands of patients to contribute data.

[Read More]

CureVac initiates phase I trial of RNAdjuvant for solid tumors

Tuesday, October 31, 2017

CureVac, a fully-integrated biotechnology company pioneering mRNA-based drugs, has initiated a phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

[Read More]

Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute

Tuesday, October 31, 2017

Boehringer Ingelheim and Sarah Cannon Research Institute announced an expansion of their strategic partnership to bring innovative treatments to cancer patients by developing novel immuno-oncology therapies. The new effort combines Boehringer Ingelheim’s oncology research and Sarah Cannon’s expertise in clinical trial design and recruitment to evaluate BI 891065, a novel and potent SMAC mimetic, alone and as a potential combination partner with PD-1-directed cancer therapy.

[Read More]

Novartis to acquire Advanced Accelerator Applications for oncology portfolio

Tuesday, October 31, 2017

Novartis has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applicationsis a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs).

[Read More]

Clinical research in the cloud, with help from Microsoft

Monday, October 30, 2017

Clinical research technology is expanding, and there is now infrastructure to back it. Last week, Parexel, a global clinical research organization, announced a new partnership with Microsoft to develop innovative cloud-based services for their clients. The collaboration will bring Parexel’s current tech offerings to the Microsoft Azure cloud platform and catalyze new developments aimed at enhancing participant engagement in clinical trials, and streamlining drug development.

[Read More]